Entity

Time filter

Source Type


Zeng H.,PLA Fourth Military Medical University | Liu Q.,PLA Fourth Military Medical University | Guan Z.,PLA Fourth Military Medical University | Zhao F.,PLA Fourth Military Medical University | And 2 more authors.
International Journal of Clinical and Experimental Pathology | Year: 2016

This study aimed to research the relationship between CD226 rs763361 and the susceptibility of lung cancer. A small case-control study of 83 healthy controls and 120 patients, was carried out in the Han population of northwest China. Whole genome DNAs were extracted and the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was used to detect the CD226 rs763361 polymorphism. Logistic regression model was used to evaluate the statistical association between the CD226 rs763361 polymorphism and the susceptibility of lung cancer. The final statistical results demonstrated that in nonsmoking group, TT genotype is more susceptible to lung cancer than CT/CC genotype in CD226 gene rs763361 (OR=3.4846, 95% CI: 1.1932-10.1762, P=0.0224,). In the female group, the TT genotype ratio of patients is higher than that of the controls (OR=3.4090, 95% CI: 0.9449-12.2987, P=0.0610), which might hint a suggestive association between CD226 rs763361 polymorphism and the susceptibility of lung cancer. Meanwhile, our results found that CD226 rs763361 polymorphism has little effect on pathology in patients group with the susceptibility of lung cancer. Our findings suggested that CD226 rs763361 polymorphism may correlate with the susceptibility of lung cancer in Chinese northwest population. Source


Zhang K.,Affiliated Hospital of The PLA Military Academy of Medical science | Wang H.,Affiliated Hospital of The PLA Military Academy of Medical science
Chinese Journal of Lung Cancer | Year: 2015

The therapeutic strategy of non-small cell lung cancer (NSCLC) is dramatically changed with the introduction of molecular targeted drugs in the last years, resulting in a series of results in histologic and molecular level. The discovery of epidermal growth factor receptor (EGFR) mutation, Kirsten rat sarcoma (KRAS) viral oncogene mutation and anaplastic lymphoma kinase (ALK) rearrangement, has profoundly influenced the development of treatment of NSCLC. Recently, there is a renewed interest in the human epidermal growth receptor 2 (HER2), where genetic alteration in NSCLC is associated with the different sensetivity of EGFR tyrosine kinase inhibitors (TKIs), to have a prognostic effect. HER2 amplification in EGFR mutation tumors may become a mechanism of acquired resistance to the TKIs. Besides, HER2 mutation may become a novel therapeutic strategy of NSCLC. © 2015, Chinese Journal of Lung Cancer. All Rights Reserved. Source


Zhao J.,Affiliated Hospital of The PLA Military Academy of Medical science | Zhang K.,Affiliated Hospital of The PLA Military Academy of Medical science | Zhang L.Y.,Affiliated Hospital of The PLA Military Academy of Medical science | Wang H.,Affiliated Hospital of The PLA Military Academy of Medical science
Chinese Journal of Lung Cancer | Year: 2015

Background and objective The aim of this study is to explore clinical efficacy of crizotinib in advanced anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer. Methods Twenty-eight patients with advanced nonsmall cell lung cancer habouring ALK positive were randomly divided into crizotinib group (n=14) and chemotherapy group (n=14). Patients in the crizotinib group were receive oral treatment with crizotinib (250 mg) twice daily. Patients in the chemotherapy group were administrated docetaxel injection (75 mg/m2) every three weeks and every patient was treated at least 3 period. Then clinical efficacy was observed after 12 mo followed-up. Results Effective rate of patients in the crizotinib group was 64.29%. It was significantly higher than that of the chemotherapy group (21.43%)(P=0.026). The stable rate of patients in the crizotinib group was 85.71%. It was significantly higher than that of the chemotherapy group 40.86% (χ2=5.600, P=0.018). Median progression free survival (PFS) of the crizotinib group was 7.0 mo. It was longer than that of the chemotherapy group (4.0 mo)(P=0.002). Conclusion Crizotinib is superior to standard chemotherapy in patients with previously treated, advanced ALK positive non-small cell lung cancer. The median PFS of patients is shorter. It can improve the quality of life about patients. © 2015, Chinese Journal of Lung Cancer. All Rights Reserved. Source

Discover hidden collaborations